At the Plan ₿ Forum in Lugano, Italian startup Generative Bionics demonstrated a humanoid robot running Tether's QVAC AI platform entirely on board, without relying on remote servers. This local AI inference approach aims to reduce latency and enhance privacy by processing sensor data within the robot itself, targeting industrial sectors like manufacturing and logistics. Tether invested €70 million in Generative Bionics, signaling strong financial backing, but independent performance data is not yet available. Future milestones to watch include independent testing, industrial deployments, and wider adoption of the AI platform.
Tether's QVAC AI platform powers a robot demonstration at the Plan ₿ Forum. For readers following the cryptocurrency market, here is Pluang's market snapshot as of Nov 02, 2026 17:31 WIB: out of 50 major cryptocurrencies, 6 rose and 42 fell today. Notable movers include ONE at Rp20 with a 1-day change of -3.36%, SNX at Rp3.230 with -3.32%, and AVAX at Rp155.253 with -3.15%.
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
